Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

April 05, 2027
Response Due
Active
Status

About this record

The issuing agency did not publish a description for this notice. The full record as GlobalGov received it is below.

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedApril 16, 2025
Procurement stageActive solicitation
Response dueApril 05, 2027
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Natalizumab (ATC-Code nach WHO: L04AG03)
Germany – Pharmaceutical products – Arzneimittel-Rabattverträge ab 01.11.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Golimumab (ATC: L04AB06)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Glatirameracetat in der Darreichungsform Injektionslösung in einer Fertigspritze, ATC L03AX13
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sulpirid, ATC N05AL01
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Infliximab zur subkutanen Applikation
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Aclidiniumbromid, ATC R03BB05
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Certolizumab pegol (ATC-Code nach WHO: L04AB05)

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.